Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps  Chengshuo Wang, MD, Hongfei Lou,

Published byEmory Haynes Modified over 5 years ago

Similar presentations

Presentation on theme: "Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps  Chengshuo Wang, MD, Hongfei Lou,"— Presentation transcript:

1 Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps  Chengshuo Wang, MD, Hongfei Lou, MD, Xiangdong Wang, MD, Yang Wang, BS, Erzhong Fan, BS, Ying Li, BS, Hong Wang, BS, Claus Bachert, MD, Luo Zhang, MD  Journal of Allergy and Clinical Immunology  Volume 135, Issue 4, Pages e6 (April 2015) DOI: /j.jaci Copyright © 2014 The Authors Terms and Conditions

2 Fig 1 Study patients' flow diagram.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

3 Fig 2 Clinical improvements in the budesonide transnasal nebulization–treated group compared with the placebo transnasal nebulization–treated group. Reductions in NP size and symptom improvements were used as primary end points. A, NP size. B, Nasal congestion. C, Rhinorhea. D, Loss of smell. E, Headache. F, TNSS. VAS, Visual analog scale. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

4 Fig 3 Inflammatory cytokines and mediators in tissue homogenates were determined by using the cytometric bead array (eotaxin, IL-5, IL-10, IL-17, and IFN-γ) and ELISA (TGF-β). A, Eotaxin. B, IL-5. C, IL-10. D, TGF-β. E, IL-17. F, IFN-γ. NS, Not significant. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

5 Fig 4 Inflammatory cells in NP tissue were analyzed before and after treatment by using H&E staining (eosinophils) and flow cytometric analysis (T-cell subsets). A, Eosinophils. B, TH2 cells. C, TH1 cells. D, TH17 cells. E, TR1 cells. F, nTreg cells. HPF, High-power field; NS, not significant. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

6 Fig 5 Picrosirius red–stained sections of polyp tissues from the same patient before and after budesonide transnasal nebulization were assessed for total collagen by using bright-field microscopy (A and B) and for collagen fibers by using polarized light microscopy (C and D) at ×200 magnification. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

7 Fig 6 Remodeling pattern shifts of NP tissues were evaluated in the budesonide transnasal nebulization–and placebo transnasal nebulization–treated groups. A, Collagen. B, Albumin. C, MMP-2. D, MMP-7. E, MMP-8. F, MMP-9. G, TIMP-1. H, TIMP-2. I, TIMP-4. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

8 Fig E1 Representative gating figures in flow cytometric analysis of TH1, TH2, TH17, TR1, and nTreg cells in tissue homogenates. A, CD4+ T cells (scatter dots in the semicircle) were gated. B, Isotype control of TH1 and TH2 cells (left lower quadrant). C, TH1 cells (IFN-γ+IL-4−CD4+ T cells, right lower quadrant) and TH2 cells (IL-4+IFN-γ−CD4+ T cells, left upper quadrant) were gated in CD4+ T cells. D, Isotype control of TH17 cells (left upper quadrant). E, TH17 cells (IL-17+CD4+ T cells, right upper quadrant) were gated in CD4+ T cells. F, Isotype control of TR1 cells (left lower quadrant). G, TR1 cells (IL-10+IL-4−CD4+ T cells, left upper quadrant) were gated in CD4+ T cells. H, Isotype control of CD25+Foxp3+ cells (left lower quadrant). I, nTreg cells (CD4+CD25+Foxp3+ T cells, right upper quadrant) were gated in CD4+ T cells. Values in dot plots indicate percentages of different cell subsets in total CD4+ T cells. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

9 Fig E2 Eosinophil infiltration in polyp tissues (×400 magnification) decreased from before (A) to after (B) treatment in the budesonide transnasal nebulization group. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

10 Fig E3 Correlation between the change in TGF-β levels and the change in nTreg cell numbers from baseline in the budesonide transnasal nebulization–treated group. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

Download ppt "Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps  Chengshuo Wang, MD, Hongfei Lou,"

Similar presentations

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy 

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy 
Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy  Erik Wambre, PhD, Jonathan.

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy  Erik Wambre, PhD, Jonathan.
Multiple-checkpoint inhibition of thymic stromal lymphopoietin–induced TH2 response by TH17-related cytokines  Sofia I. Bogiatzi, BSc, Maude Guillot-Delost,

Multiple-checkpoint inhibition of thymic stromal lymphopoietin–induced TH2 response by TH17-related cytokines  Sofia I. Bogiatzi, BSc, Maude Guillot-Delost,
The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,

The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,
Anju T. Peters, MD, Atsushi Kato, PhD, Ning Zhang, PhD, David B

Anju T. Peters, MD, Atsushi Kato, PhD, Ning Zhang, PhD, David B
Vitamin D3 treatment of vitamin D–insufficient asthmatic patients does not alter immune cell function  Brandy Reid, MS, Pierre-Olivier Girodet, MD, PhD,

Vitamin D3 treatment of vitamin D–insufficient asthmatic patients does not alter immune cell function  Brandy Reid, MS, Pierre-Olivier Girodet, MD, PhD,
Forkhead box protein 3 in human nasal polyp regulatory T cells is regulated by the protein suppressor of cytokine signaling 3  Feng Lan, MD, Nan Zhang,

Forkhead box protein 3 in human nasal polyp regulatory T cells is regulated by the protein suppressor of cytokine signaling 3  Feng Lan, MD, Nan Zhang,
Critical link between glycogen synthase kinase 3β and forkhead box P3 in patients with chronic rhinosinusitis with nasal polyps  Xingmei Wu, MD, Sihua.

Critical link between glycogen synthase kinase 3β and forkhead box P3 in patients with chronic rhinosinusitis with nasal polyps  Xingmei Wu, MD, Sihua.
Correlation of allergen-specific T follicular helper cell counts with specific IgE levels and efficacy of allergen immunotherapy  Yin Yao, MD, Cai-Ling.

Correlation of allergen-specific T follicular helper cell counts with specific IgE levels and efficacy of allergen immunotherapy  Yin Yao, MD, Cai-Ling.
Forkhead box protein 3 in human nasal polyp regulatory T cells is regulated by the protein suppressor of cytokine signaling 3  Feng Lan, MD, Nan Zhang,

Forkhead box protein 3 in human nasal polyp regulatory T cells is regulated by the protein suppressor of cytokine signaling 3  Feng Lan, MD, Nan Zhang,
The antimicrobial protein short palate, lung, and nasal epithelium clone 1 (SPLUNC1) is differentially modulated in eosinophilic and noneosinophilic chronic.

The antimicrobial protein short palate, lung, and nasal epithelium clone 1 (SPLUNC1) is differentially modulated in eosinophilic and noneosinophilic chronic.
Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois  Bruce K. Tan, MD, MS, Aiko I. Klingler, PhD,

Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois  Bruce K. Tan, MD, MS, Aiko I. Klingler, PhD,
Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy 

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy 
IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis  Hyun-Woo Shin, MD, PhD, Dong-Kyu Kim, MD, Min-Hyun Park, MD,

IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis  Hyun-Woo Shin, MD, PhD, Dong-Kyu Kim, MD, Min-Hyun Park, MD,
Anju T. Peters, MD, Atsushi Kato, PhD, Ning Zhang, PhD, David B

Anju T. Peters, MD, Atsushi Kato, PhD, Ning Zhang, PhD, David B
Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese  Ping-Ping Cao, MD, Hua-Bin Li, MD, PhD, Bao-Feng.

Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese  Ping-Ping Cao, MD, Hua-Bin Li, MD, PhD, Bao-Feng.
Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation 

Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation 
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
T-cell regulation during viral and nonviral asthma exacerbations

T-cell regulation during viral and nonviral asthma exacerbations
Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels  Miguel L. Stein, MD, Joyce M. Villanueva,

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels  Miguel L. Stein, MD, Joyce M. Villanueva,

Similar presentations

Ads by Google